Stock Analysis on Net

Shockwave Medical Inc. (NASDAQ:SWAV)

Present Value of Free Cash Flow to the Firm (FCFF)

Microsoft Excel

In discounted cash flow (DCF) valuation techniques the value of the stock is estimated based upon present value of some measure of cash flow. Free cash flow to the firm (FCFF) is generally described as cash flows after direct costs and before any payments to capital suppliers.


Intrinsic Stock Value (Valuation Summary)

Shockwave Medical Inc., free cash flow to the firm (FCFF) forecast

US$ in thousands, except per share data

Microsoft Excel
Year Value FCFFt or Terminal value (TVt) Calculation Present value at 11.71%
01 FCFF0 165,951
1 FCFF1 164,949 = 165,951 × (1 + -0.60%) 147,652
2 FCFF2 168,454 = 164,949 × (1 + 2.13%) 134,978
3 FCFF3 176,632 = 168,454 × (1 + 4.85%) 126,690
4 FCFF4 190,028 = 176,632 × (1 + 7.58%) 122,006
5 FCFF5 209,627 = 190,028 × (1 + 10.31%) 120,477
5 Terminal value (TV5) 16,511,651 = 209,627 × (1 + 10.31%) ÷ (11.71%10.31%) 9,489,563
Intrinsic value of Shockwave Medical Inc. capital 10,141,366
Less: Convertible and long-term debt, current and noncurrent (fair value) 730,500
Intrinsic value of Shockwave Medical Inc. common stock 9,410,866
 
Intrinsic value of Shockwave Medical Inc. common stock (per share) $251.65
Current share price $330.00

Based on: 10-K (reporting date: 2023-12-31).

Disclaimer!
Valuation is based on standard assumptions. There may exist specific factors relevant to stock value and omitted here. In such a case, the real stock value may differ significantly form the estimated. If you want to use the estimated intrinsic stock value in investment decision making process, do so at your own risk.


Weighted Average Cost of Capital (WACC)

Shockwave Medical Inc., cost of capital

Microsoft Excel
Value1 Weight Required rate of return2 Calculation
Equity (fair value) 12,340,949 0.94 12.34%
Convertible and long-term debt, current and noncurrent (fair value) 730,500 0.06 1.19% = 1.50% × (1 – 21.00%)

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in thousands

   Equity (fair value) = No. shares of common stock outstanding × Current share price
= 37,396,816 × $330.00
= $12,340,949,280.00

   Convertible and long-term debt, current and noncurrent (fair value). See details »

2 Required rate of return on equity is estimated by using CAPM. See details »

   Required rate of return on debt. See details »

   Required rate of return on debt is after tax.

   Estimated (average) effective income tax rate
= (73.78% + 21.00% + 21.00% + 21.00% + 21.00%) ÷ 5
= 21.00%

WACC = 11.71%


FCFF Growth Rate (g)

FCFF growth rate (g) implied by PRAT model

Shockwave Medical Inc., PRAT model

Microsoft Excel
Average Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Interest expense 6,905 1,886 1,096 1,212 944
Net income (loss) 147,278 215,996 (9,136) (65,699) (51,109)
 
Effective income tax rate (EITR)1 73.78% 21.00% 21.00% 21.00% 21.00%
 
Interest expense, after tax2 1,810 1,490 866 957 746
Interest expense (after tax) and dividends 1,810 1,490 866 957 746
 
EBIT(1 – EITR)3 149,088 217,486 (8,270) (64,742) (50,363)
 
Debt, current portion 5,500 3,300 6,667
Convertible debt, noncurrent portion 731,863
Debt, noncurrent portion 24,198 11,630 13,319 7,152
Stockholders’ equity 668,677 511,316 241,830 225,654 192,653
Total capital 1,400,540 535,514 258,960 242,273 206,472
Financial Ratios
Retention rate (RR)4 0.99 0.99
Return on invested capital (ROIC)5 10.65% 40.61% -3.19% -26.72% -24.39%
Averages
RR 0.99
ROIC -0.61%
 
FCFF growth rate (g)6 -0.60%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2023 Calculations

2 Interest expense, after tax = Interest expense × (1 – EITR)
= 6,905 × (1 – 73.78%)
= 1,810

3 EBIT(1 – EITR) = Net income (loss) + Interest expense, after tax
= 147,278 + 1,810
= 149,088

4 RR = [EBIT(1 – EITR) – Interest expense (after tax) and dividends] ÷ EBIT(1 – EITR)
= [149,0881,810] ÷ 149,088
= 0.99

5 ROIC = 100 × EBIT(1 – EITR) ÷ Total capital
= 100 × 149,088 ÷ 1,400,540
= 10.65%

6 g = RR × ROIC
= 0.99 × -0.61%
= -0.60%


FCFF growth rate (g) implied by single-stage model

g = 100 × (Total capital, fair value0 × WACC – FCFF0) ÷ (Total capital, fair value0 + FCFF0)
= 100 × (13,071,449 × 11.71%165,951) ÷ (13,071,449 + 165,951)
= 10.31%

where:

Total capital, fair value0 = current fair value of Shockwave Medical Inc. debt and equity (US$ in thousands)
FCFF0 = the last year Shockwave Medical Inc. free cash flow to the firm (US$ in thousands)
WACC = weighted average cost of Shockwave Medical Inc. capital


FCFF growth rate (g) forecast

Shockwave Medical Inc., H-model

Microsoft Excel
Year Value gt
1 g1 -0.60%
2 g2 2.13%
3 g3 4.85%
4 g4 7.58%
5 and thereafter g5 10.31%

where:
g1 is implied by PRAT model
g5 is implied by single-stage model
g2, g3 and g4 are calculated using linear interpoltion between g1 and g5

Calculations

g2 = g1 + (g5g1) × (2 – 1) ÷ (5 – 1)
= -0.60% + (10.31%-0.60%) × (2 – 1) ÷ (5 – 1)
= 2.13%

g3 = g1 + (g5g1) × (3 – 1) ÷ (5 – 1)
= -0.60% + (10.31%-0.60%) × (3 – 1) ÷ (5 – 1)
= 4.85%

g4 = g1 + (g5g1) × (4 – 1) ÷ (5 – 1)
= -0.60% + (10.31%-0.60%) × (4 – 1) ÷ (5 – 1)
= 7.58%